Yale Cancer Center at 2015 ASCO Annual Meeting

Highlights include: new immunotherapy response/survival data for immunotherapy for bladder and lung cancers; advances in small cell lung cancer; exercise and quality of life for cancer survivors; expanding indications for checkpoint blockade

Clinical Science Symposiums:

Saturday, May 30; 9:03 AM - 9:15 AM

Location: E Hall D1

Immunotherapy for Every Patient: Check Your Enthusiasm

Roy S. Herbst, MD, PhD

Monday, June 1; 3:48 PM - 4:00 PM

Location: E Arie Crown Theater

Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies

Madhav V. Dhodapkar, MBBS

Oral Abstract Sessions:

Saturday, May 30; 4:36 PM - 4:48 PM

Location: E Hall D1

Small Cell Lung Cancer: A Glimpse of Light

Roy S. Herbst, MD, PhD

Monday, June 1; 9:48 AM - 10:00 AM

Location: S102

Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women's Activity and Lifestyle Study in Connecticut (WALC).

Yang Zhou, MD, MPH

Monday, June 1; 10:24 AM - 10:36 AM

Location: S102

Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors.

Melinda L. Irwin, PhD, MPH

Monday, June 1; 12:09 PM - 12:21 PM

Location: E450

The Potential Role of Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphoma

Francine M. Foss, MD

Monday, June 1; 9:57 AM - 10:09 AM

Location: E Arie Crown Theater

A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

Daniel P. Petrylak, MD

Monday, June 1; 3:15 PM - 3:27 PM

Location: S100bc

HPV and Epstein-Barr Virus-Related Head and Neck Cancer: Deintensification and Surveillance

Barbara Burtness, MD

Poster Discussion Session:

Saturday, May 30; 3:00 PM - 3:12 PM/ Discussing Abstracts: 3009, 3010, 3011, 3012

Location: S406

Expanding Indications of Checkpoint Blockade

Harriet Kluger, MD

Poster Sessions: S Hall A

Saturday, May 30; 8:00 AM - 11:30 AM

Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.

Tara Sanft, MD

A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.

Maysa Abu-Khalaf, MD

A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).

Maysa Abu-Khalaf, MD

Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.

Mehmet Altan, MD

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.

Sarah Schellhorn Mougalian, MD

Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.

Kurt Alex Schalper, MD/PhD

Poster Sessions: S Hall A

Saturday, May 30; 1:15 PM - 4:45 PM

Distress in cancer survivors attending a multidisciplinary survivorship clinic.

Tara Sanft, MD

Trends and regional variation of end-of-life cancer care in the Medicare program.

Shi-Yi Wang, MD, PhD

Contemporary national trends of prostate cancer screening among privately insured patients in the United States.

Simon P. Kim, MD, MPH

Poster Sessions: S Hall A2

Monday, June 1; 8:00 AM - 11:30 AM

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

Scott Gettinger, MD

Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases

Sarah Goldberg, MD

"The burden upon me": The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.

Carolyn Jean Presley, MD

Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer.

Elyn H. Wang, BS

Clinical diagnostic utility of a blood-based multi-transcriptome assay for gastroenteropancreatic disease.

Irvin Mark Modlin, MD, PhD

Poster Sessions: S Hall A

Monday, June 1; 1:15 PM - 4:45 PM

A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).

Anton Safonov, BS

Education Sessions:

Saturday, May 30; 1:15 PM - 1:35 PM

Location: E Hall D1

Recent Positive Clinical Trials and Data in Context of Study Results, Design, and Endpoints

Rogerio Lilenbaum, MD

Tuesday, June 2; 11:45 AM - 12:00 PM

Location: E450

Lung Cancer

Rogerio Lilenbaum, MD